A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France

Vox Sanguinis

Volumn 104, Issue 4, 2013, Pages 337-341

  Bost, V ^a   Odent Malaure, H ^a   Chavarin, P ^a   Benamara, H ^a   Fabrigli, P ^a   Garraud, O ^a,b  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Adverse events; Fresh frozen plasma; Haemovigilance; Therapeutic plasma; Transfusion safety

Indexed keywords

AMOTOSALEN; DETERGENT; FRESH FROZEN PLASMA; METHYLENE BLUE;

ARTICLE; BLOOD SAFETY; DATA BASE; DISEASE SEVERITY; ERYTHROCYTE; FRANCE; HOSPITAL POLICY; HUMAN; INCIDENCE; INFECTION CONTROL; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

BLOOD SAFETY; BLOOD TRANSFUSION; DATA COLLECTION; FRANCE; HUMANS; PLASMA; RETROSPECTIVE STUDIES;

EID: 84876742256     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12007     Document Type: Article

References (18)

1. Rapport d'Activité de l'Etablissement Français du Sang 2010, Saint-Denis, France. http://www.dondusang.net/content/medias/media1694_iJagqYaVeYtANzP.pdf? FinalFileName=Rapport_dactivit%E9.pdf.
2. Epstein JS: Alternative in assuring blood safety: an overview. Biologicals 2010; 38:31-35.
3. Nubret K, Delhoume M, Orsel I, et al.: Anaphylactic shock to fresh Frozen plasma in activated with methylene blue. Transfusion 2011; 51:125-128.
4. Council of Europe. Quality of Medicines & Health Care of the Council of Europe (EDQM): Guide to the Preparation, Use and Quality Assurance of Blood Components, 16th edn. Strasbourg, European Directorate for the Quality of Medicines & Health Care (EDQM), 2010.
5. Sandler SG: The status of pathogen reduced plasma. Transfus Apher Sci 2010; 43:393-399.
6. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS): Transfusion de Plasma frais congelé: produits, indications. Transfus Clin Biol 2002; 9:322-332.
7. Agence Nationale du Médicament et des Produits de Santé et Haute Autorité de Santé, Saint-Denis, mai 2012. http://www.hassante.fr/portail/upload/docs/application/pdf/201206/12irp07_reco_transfusion_de_plasma.pdf.
8. Chabanel A, Masse M, Begue S, EFS group of blood component QC laboratory managers: National French observatory of the quality of blood components for transfusion. Transfus Clin Biol 2008; 15:85-90.
9. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57:289-300.
10. Freeman GH, Halton JH: Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 1951; 38:141-149.
11. Agence Nationale de Santé et de Sécurité du Médicament 2010, Rapport d'activité d'Hémovigilance2010. http://www.ansm.sante.fr/content/download/.../Rapport Hemovigilance2010.pdf.
12. Sachs UJ: Non-infectious serious hazards in plasma transfusion. Transfus Apher Sci 2010; 43:381-386.
13. Gillis BM, Looney MR, Gropper MA: Reducing non-infectious risks of blood transfusion. Anesthesiology 2011; 115:635-649.
14. Cazenave JP, Waller C, Kientz D, et al.: An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photo chemical treatment. Transfusion 2010; 50:1210-1219.
15. Cazenave JP: Inactivation photochimique des pathogènes des plaquettes et du plasma: cinq ans d'utilisation clinique de routine et d'hémovigilance. Vers un changement de Paradigme de la sécurité en transfusion. Transfus Clin Biol 2011; 18:53-61.
16. Funk MB, Guenay S, Lohmann A, et al.: Benefit of transfusion related acute lung injury risk minimization measures in German haemovigilance data (20062010). Vox Sang 2012; 102:317-323.
17. Ozier Y, Muller JY, Mertes PM, et al.: Transfusion related acute lung injury: reports to the French Haemovigilance Network 2007 trough 2008. Transfusion 2011; 41:2102-2110.
18. Hacquart M, Lecompte T, Blecourt B, et al.: Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen reduced plasmas. Vox Sang 2012; 102:354-361.